(BWXT) BWX Technologies - Overview
Stock: Naval Reactors, Nuclear Fuel, Medical Isotopes, Components
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.78% |
| Yield on Cost 5y | 1.87% |
| Yield CAGR 5y | 4.46% |
| Payout Consistency | 99.1% |
| Payout Ratio | 37.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 44.8% |
| Relative Tail Risk | -21.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.43 |
| Alpha | 58.13 |
| Character TTM | |
|---|---|
| Beta | 1.153 |
| Beta Downside | 1.174 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.87% |
| CAGR/Max DD | 1.55 |
Description: BWXT BWX Technologies December 19, 2025
BWX Technologies (BWXT) designs, manufactures, and services nuclear-related components for government and commercial customers across the U.S., Canada, and other markets. It operates two segments-Government Operations, which supplies naval nuclear parts, defense-grade fuel, and uranium down-blending, and Commercial Operations, which produces steam generators, fuel handling systems, high-level waste containers, and medical radioisotopes.
In FY 2023 the company reported ≈ $1.2 billion in revenue, with a backlog of roughly $1.5 billion-about 70 % of which is tied to long-term U.S. Department of Defense and Navy contracts. BWXT’s order flow is heavily influenced by federal nuclear-fuel procurement cycles and the emerging small-modular reactor (SMR) pipeline, which the firm is positioning to serve through its precision-machined components and engineering services.
The broader nuclear sector is driven by three macro forces: (1) U.S. policy incentives for carbon-free generation that sustain demand for reactor refurbishment and new builds; (2) rising government spending on defense-related nuclear capabilities, which underpins BWXT’s Navy contracts; and (3) the growing need for safe storage solutions for spent fuel, a market where BWXT’s high-integrity containers have limited competition.
For a deeper quantitative view, you may find ValueRay’s detailed financial dashboards and peer benchmarks helpful.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 307.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 5.41 > 1.0 |
| NWC/Revenue: 14.96% < 20% (prev 20.33%; Δ -5.38% < -1%) |
| CFO/TA 0.17 > 3% & CFO 629.7m > Net Income 307.0m |
| Net Debt (1.43b) to EBITDA (520.3m): 2.74 < 3 |
| Current Ratio: 1.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (91.8m) vs 12m ago -0.11% < -2% |
| Gross Margin: 23.54% > 18% (prev 0.25%; Δ 2329 % > 0.5%) |
| Asset Turnover: 90.92% > 50% (prev 91.02%; Δ -0.11% > 0%) |
| Interest Coverage Ratio: 9.72 > 6 (EBITDA TTM 520.3m / Interest Expense TTM 43.0m) |
Altman Z'' 4.75
| A: 0.12 (Total Current Assets 1.10b - Total Current Liabilities 646.6m) / Total Assets 3.78b |
| B: 0.65 (Retained Earnings 2.45b / Total Assets 3.78b) |
| C: 0.12 (EBIT TTM 418.3m / Avg Total Assets 3.36b) |
| D: 0.95 (Book Value of Equity 2.42b / Total Liabilities 2.54b) |
| Altman-Z'' Score: 4.75 = AA |
Beneish M -2.84
| DSRI: 0.93 (Receivables 915.6m/859.7m, Revenue 3.06b/2.68b) |
| GMI: 1.06 (GM 23.54% / 24.96%) |
| AQI: 1.29 (AQ_t 0.30 / AQ_t-1 0.23) |
| SGI: 1.14 (Revenue 3.06b / 2.68b) |
| TATA: -0.09 (NI 307.0m - CFO 629.7m) / TA 3.78b) |
| Beneish M-Score: -2.84 (Cap -4..+1) = A |
What is the price of BWXT shares?
Over the past week, the price has changed by -4.01%, over one month by +0.97%, over three months by +1.83% and over the past year by +76.17%.
Is BWXT a buy, sell or hold?
- StrongBuy: 6
- Buy: 3
- Hold: 1
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the BWXT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 224.4 | 13.8% |
| Analysts Target Price | 224.4 | 13.8% |
| ValueRay Target Price | 298.1 | 51.2% |
BWXT Fundamental Data Overview February 07, 2026
P/E Forward = 45.4545
P/S = 5.6018
P/B = 13.9966
P/EG = 2.31
Revenue TTM = 3.06b USD
EBIT TTM = 418.3m USD
EBITDA TTM = 520.3m USD
Long Term Debt = 1.50b USD (from longTermDebt, last quarter)
Short Term Debt = 12.5m USD (from shortTermDebt, last quarter)
Debt = 1.51b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.43b USD (from netDebt column, last quarter)
Enterprise Value = 18.56b USD (17.14b + Debt 1.51b - CCE 82.7m)
Interest Coverage Ratio = 9.72 (Ebit TTM 418.3m / Interest Expense TTM 43.0m)
EV/FCF = 40.10x (Enterprise Value 18.56b / FCF TTM 462.8m)
FCF Yield = 2.49% (FCF TTM 462.8m / Enterprise Value 18.56b)
FCF Margin = 15.13% (FCF TTM 462.8m / Revenue TTM 3.06b)
Net Margin = 10.04% (Net Income TTM 307.0m / Revenue TTM 3.06b)
Gross Margin = 23.54% ((Revenue TTM 3.06b - Cost of Revenue TTM 2.34b) / Revenue TTM)
Gross Margin QoQ = 21.82% (prev 25.05%)
Tobins Q-Ratio = 4.91 (Enterprise Value 18.56b / Total Assets 3.78b)
Interest Expense / Debt = 0.93% (Interest Expense 14.0m / Debt 1.51b)
Taxrate = 23.59% (25.4m / 107.6m)
NOPAT = 319.6m (EBIT 418.3m * (1 - 23.59%))
Current Ratio = 1.71 (Total Current Assets 1.10b / Total Current Liabilities 646.6m)
Debt / Equity = 1.22 (Debt 1.51b / totalStockholderEquity, last quarter 1.24b)
Debt / EBITDA = 2.74 (Net Debt 1.43b / EBITDA 520.3m)
Debt / FCF = 3.08 (Net Debt 1.43b / FCF TTM 462.8m)
Total Stockholder Equity = 1.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.13% (Net Income 307.0m / Total Assets 3.78b)
RoE = 26.66% (Net Income TTM 307.0m / Total Stockholder Equity 1.15b)
RoCE = 15.79% (EBIT 418.3m / Capital Employed (Equity 1.15b + L.T.Debt 1.50b))
RoIC = 12.91% (NOPAT 319.6m / Invested Capital 2.48b)
WACC = 9.39% (E(17.14b)/V(18.64b) * Re(10.16%) + D(1.51b)/V(18.64b) * Rd(0.93%) * (1-Tc(0.24)))
Discount Rate = 10.16% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.11%
[DCF Debug] Terminal Value 76.87% ; FCFF base≈358.3m ; Y1≈441.9m ; Y5≈752.7m
Fair Price DCF = 92.70 (EV 9.90b - Net Debt 1.43b = Equity 8.48b / Shares 91.4m; r=9.39% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -17.75 | EPS CAGR: -45.01% | SUE: -4.0 | # QB: 0
Revenue Correlation: 86.56 | Revenue CAGR: 10.69% | SUE: 3.11 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.97 | Chg30d=+0.022 | Revisions Net=+1 | Analysts=6
EPS next Year (2026-12-31): EPS=4.30 | Chg30d=+0.046 | Revisions Net=+0 | Growth EPS=+12.4% | Growth Revenue=+16.5%